Semaglutide base is the active ingredient used in FDA-approved products
The continued expansion of biosimilars and complex biologics will further democratise access to cutting-edge treatments worldwide, while the rapid growth of CRDMOs will establish India as a preferred destination for high-value outsourcing in an era of supply-chain reconfiguration.'' Domestic pharma is scaling up R&D, particularly for advanced biologics, GLs, antibody-drug conjugate, cell and gene therapies, and pivoting from simple to complex generics, according to Srikanth Mahadevan, director, Deloitte India.Further, "private equity interest will remain a dominant theme for healthcare providers, particularly hospitals, medical services and digital health
Among other things, the companies failed to adequately test medicine components for diethylene glycol (DEG) or ethylene glycol (EG) contamination before using them
Coverage criteria are written by the payer, not by the FDA, and many plans carry a categorical exclusion for anti-obesity medications that no amount of clinical documentation will overcome
And it reduces gastrointestinal motility, further slowing food transit through the digestive system